Through research initiated in her capacity as a Scientist with the Canadian Blood Services (CBS) at the CBR, Dr. Elisabeth Maurer has invented a new test, referred to as ThromboLUX, to determine the quality of platelets for transfusion. In 2007 Dr. Maurer and her team conducted a successful pilot study at the Vancouver General Hospital and at the UBC that demonstrated a direct correlation of the ThromboLUX platelet quality score with transfusion outcome (CoDIVO). The results have recently been published in the journal, Transfusion.

The clinical importance of the CoDIVO Study led to commercialization of the ThromboLUX technology and the founding in 2008 of LightIntegra Technology Inc. (www.lightintegra.com). LightIntegra recently was the winner of the Award for the Best Pre-revenue Company at the 2009 Annual Vancouver Angel Forum and received first prize in the 2009 New Ventures BC Business Plan Competition.